Regeneron Pharmaceuticals Inc
NASDAQ: REGN
$689.50
-$28.66 (-4.0%)
Closing Price on March 12, 2025
REGN Articles
Alnylam Pharma and Regeneron Pharma shares dipped on Monday despite announcing a collaboration to discover, develop and commercialize new RNA interference therapeutics for a broad range of diseases.
Published:
In an incredible move for adolescent patients 12 to 17 years of age, the U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for with moderate-to-severe atopic dermatitis.
Published:
Last Updated:
The top analyst upgrades, downgrades and initiations seen on Friday included Bed Bath & Beyond, CBOE, eBay, Etsy, Intel, Netflix, Nokia, Snap, United Technologies and Vonage.
Published:
Last Updated:
The top analyst upgrades, downgrades and initiations seen on Friday included Activision Blizzard, BioMarin Pharmaceuticals, Ciena, Delta Air Lines, GlaxoSmithKline, Procter & Gamble, Regeneron...
Published:
Last Updated:
The included Achaogen, Apple, Athenahealth, Crocs, Finisar, Jabil, Michael Kors, Occidental Petroleum, Starbucks and Walt Disney.
Published:
Last Updated:
Thursday was a positive day for the broad U.S. markets. All three major indices recovered handily from Wednesday’s drop. Crude oil made a solid gain in the session. The S&P 500 sectors were...
Published:
Last Updated:
Merrill Lynch recently highlighted sectors it considers a good opportunity now that are likely to outperform in the near term, and the sector that rated highest was biotechnology.
Published:
Last Updated:
Teva and Regeneron both saw handy gains on Thursday after the companies posted positive topline results from their late-stage trial of fasinumab in patients with chronic pain from osteoarthritis...
Published:
Last Updated:
Regeneron Pharmaceuticals is facing some difficulty after it received an update from the FDA on Eylea (aflibercept) Injection in patients with wet age-related macular degeneration.
Published:
Last Updated:
It’s no surprise that it was only a matter of time before the usage and storage of big data and analytics would come to the health care sector, and many of the top companies are starting to...
Published:
Last Updated:
Friday was a relatively positive day for the broad U.S. markets. Although crude oil backed off, it is still holding just above the $70 price level. The S&P 500 sectors were split down the middle.
Published:
Last Updated:
Regeneron Pharmaceuticals and Sanofi are committing to lowering the price of the anti-cholesterol drug Praluent.
Published:
Last Updated:
Rheumatoid arthritis is an autoimmune disease that attacks tissues within the joints, and it is a major target of U.S. and foreign biotechnology and pharmaceutical companies.
Published:
Last Updated:
The top analyst upgrades, downgrades and other research calls from Monday include Alcoa, CEMEX, Comerica, Facebook, General Motors, Incyte, Proofpoint and Regeneron Pharmaceuticals.
Published:
Last Updated:
While chasing what portfolio managers own isn’t always the best idea, many people have made a lot of money by simply mimicking what legendary investors like Warren Buffett hold.
Published:
Last Updated:
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.